Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

Patent metadata

Field	Value
Publication number	US-10016463-B2
Application number	US-201314418557-A
Country	US
Kind code	B2
Filing date	Jul 30, 2013
Priority date	Aug 1, 2012
Publication date	Jul 10, 2018
Grant date	Jul 10, 2018

Abstract

The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

First claim

What is claimed is:

1. A method for treating pulmonary hypertension, comprising:
providing isolated endothelial progenitor cells (EPCs), wherein the EPCs are isolated from a human being, a tissue, or cell culture;
treating the isolated EPCs in vitro or ex vivo with a prostacyclin during expansion of the EPCs, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic activity; and
administering a composition comprising the treated EPCs to a subject suffering from pulmonary hypertension.

2. The method of claim 1 , wherein the prostacyclin is selected from the group consisting of epoprostenol sodium, treprostinil, and iloprost.

3. The method of claim 1 , wherein the subject is a human being.

4. The method of claim 1 , wherein the EPCs are autologous.

5. The method of claim 1 , wherein the EPCs are isolated from the blood of the subject suffering from pulmonary hypertension.

6. The method of claim 1 , wherein the EPCs are endothelial colony forming cells.

7. The method of claim 1 , wherein the EPCs are genetically modified.

8. The method of claim 1 , wherein the composition is a pharmaceutical composition further comprising at least one pharmaceutically-acceptable carrier.

9. The method of claim 1 , wherein the composition further comprises at least one therapeutic agent other than EPCs.

10. The method of claim 1 , wherein administering the composition promotes pulmonary vascular repair.

11. The method of claim 1 , wherein the composition is co-administered with at least one growth factor.

12. The method of claim 11 , wherein the growth factor is selected from the group consisting of FGF, VEGF-A, VEGF-B, BMP-4, and TGF-Beta.

13. The method of claim 1 , wherein the composition is co-administered with (i) mesenchymal stem cells or (ii) a culture medium that has been in contact with mesenchymal stem cells and that contains one or more components thereof.

14. The method of claim 1 , wherein the composition is co-administered with a prostacyclin.

15. The method of claim 5 , wherein the subjected is pretreated with a prostacyclin before the isolation of the EPCs.

16. The method of claim 1 , wherein the prostacyclin is treprostinil.

Assignees

• United Therapeutics Corp

Inventors

• Jeffs Roger
• Petersen Thomas
• Ilagan Roger M
• Wade Michael

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title